The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 20, 2022
Filed:
Jan. 22, 2019
Applicant:
G1 Therapeutics, Inc., Research Triangle Park, NC (US);
Inventors:
Jay Copeland Strum, Hillsborough, NC (US);
John E. Bisi, Apex, NC (US);
Patrick Joseph Roberts, Durham, NC (US);
Jessica A. Sorrentino, Durham, NC (US);
Hannah S. White, Chapel Hill, NC (US);
Assignee:
G1 Therapeutics, Inc., Research Triangle Park, NC (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4985 (2006.01); A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61K 31/527 (2006.01); A61K 31/5377 (2006.01); A61K 51/04 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61K 31/499 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4985 (2013.01); A61K 31/499 (2013.01); A61K 31/519 (2013.01); A61K 31/527 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); A61K 47/68 (2017.08); A61K 51/0459 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01);
Abstract
This invention directed to methods for treating select RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders using CDK4/6 inhibitors in specific dosing and combination or alternation regimes. In one aspect, treatments of select RB-positive cancers are disclosed using specific CDK4/6 inhibitors in combination or alternation with a Bruton's tyrosine kinase (BTK) inhibitor.